Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 1.5 mg starting dose available in early January for $149 per month with savings offers; Wegovy® pill is being produced in the US and robust supply is on-hand Wegovy® brand is the only GLP-1 indicated for weight loss proven to help prevent life-threatening CV events for adults […]

Read more

It’s a common refrain among many of us at the start of a new year: I need to lose some weight.  Nearly three-quarters of Americans are overweight, and obesity is increasing in the rest of the world as well. Demand for expensive medical treatments like surgery or GLP-1 medications is soaring, at a high cost to health care systems. A new working paper shows that generative artificial intelligence can help people lower their body mass index, and at a low […]

Read more

Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose of Wegovy® pill (1.5 mg) available today for only $149 per month (or $5 per day) via easy to access self-pay offer Wegovy® pill now broadly available through 70,000+ US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, […]

Read more

When Terra Field started taking Wegovy for weight loss in 2022, she finally understood what satiety truly felt like. “It felt the way I thought my body should have been operating the entire time,” says Field, who adds that she has dealt with constant food cravings and binge eating since childhood. Field, now age 43, had lost more than 100 pounds in two and a half years, and she says that the relief from “food noise,” a […]

Read more

The global rise in obesity and diet-related non-communicable diseases has sparked growing interest in pharmacological treatments. This is especially true of glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists, such as tirzepatide, both now considered notable weight management solutions. 1 But while they may offer short-term benefits for some, they come with limitations and should not be treated as substitutes for action on unhealthy food environments driving the obesity epidemic. […]

Read more

The popular diabetes and weight-loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug. Diabetic retinopathy develops when chronically high blood sugar damages the blood vessels lining the back of the eye, and affects nearly 10 million people in the United States. Previous studies suggested […]

Read more

Share on PinterestA small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images A recent small study found that reduced GLP-1 frequency may help people maintain their weight loss. The study shows that people who dosed as little as once every two months maintained weight loss and other improved health markers. Tapering GLP-1s may not be right for everyone, but the […]

Read more

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. In early March the U.S. Food and Drug Administration sent a warning letter to Novo Nordisk, the maker of Ozempic and Wegovy, saying the company had failed to disclose potential risks associated with taking these drugs. The agency alleged that Novo Nordisk failed to properly report and/or follow up on three deaths of individuals who were taking semaglutide, the key ingredient in Ozempic […]

Read more

Local News The change will leave an estimated 22,000 MassHealth members on the hook to pay out of pocket for the pricy GLP-1s and other anti-obesity drugs. Beginning July 1, MassHealth will stop covering GLP-1 and other anti-obesity medications prescribed solely for weight loss, a policy change expected to affect at least 22,000 Massachusetts residents. The move, announced as part of Gov. Maura Healey’s fiscal 2027 budget proposal in January, is expected to save an estimated $15 […]

Read more